Testing effectiveness (Phase 2)Study completedNCT03366142
What this trial is testing
Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology
Who this might be right for
LAD1
National Institute of Allergy and Infectious Diseases (NIAID) 6